Regulatory FDA’s ODAC delivers one loss, one win for AstraZeneca PharmaphorumThe FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.OncologyRead full story pharminent May 1, 2026 (Last updated: May 1, 2026) Pharmaphorum The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant. Oncology Read full story Post navigation Previous: Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitationNext: Amgen positions MariTide as potential ‘best monthly’ obesity drug Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026